Novo Nordisk registers Phase 1 study of oral obesity candidate NNC6022-0004
A new phase1 trial testing NNC6022-0004 in healthy adults and people with obesity is listed as recruiting on ClinicalTrials.gov.
Novo Nordisk's clinical trial registry activity this week includes one study update.
- Novo Nordisk A/S is sponsoring a phase1 study, "An NNC6022-0004 Single and Multiple Ascending Dose Study Investigating Safety, Tolerability, Pharmacokinetics, Food Effect and Target Engagement in Healthy Adults Including a Single Cohort in Adults Living With Obesity" (NCT07693868), which is listed as recruiting, with an estimated enrollment of 128 participants.1 The study covers obesity and elevated high-sensitivity C-reactive protein (hsCRP)1 and tests NNC6022-0004 administered orally in capsule form as a single or multiple ascending dose, or under fed and fasted conditions, against placebo.1 The listing shows an actual start date of 2026-07-06, with an estimated primary completion date of 2027-08-03.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.